Robert J Motzer Selected Research

Renal Cell Carcinoma (Grawitz Tumor)

10/2022	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
2/2022	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
1/2022	Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
1/2022	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
1/2022	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.
1/2022	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
1/2022	Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.
1/2022	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
1/2022	Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
1/2022	Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert J Motzer Research Topics

Disease

227	Renal Cell Carcinoma (Grawitz Tumor) 10/2022 - 01/2002
118	Neoplasms (Cancer) 02/2022 - 01/2002
38	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2021 - 11/2002
24	Fatigue 10/2020 - 01/2007
21	Disease Progression 09/2021 - 01/2002
18	Hypertension (High Blood Pressure) 01/2022 - 11/2007
18	Neoplasm Metastasis (Metastasis) 12/2018 - 11/2003
16	Kidney Neoplasms (Kidney Cancer) 01/2022 - 08/2004
14	Teratoma (Teratoid Tumor) 10/2019 - 10/2003
11	Testicular Neoplasms (Testicular Cancer) 09/2016 - 11/2003
8	Hypoxia (Hypoxemia) 02/2018 - 12/2006
7	Exanthema (Rash) 10/2019 - 05/2007
7	Diarrhea 10/2018 - 01/2007
5	Stomatitis 01/2020 - 09/2007
5	Nonseminomatous germ cell tumor 08/2018 - 02/2004
5	Hand-Foot Syndrome 12/2015 - 10/2008
4	Dyspnea (Shortness of Breath) 10/2018 - 06/2008
4	Hyperglycemia 10/2016 - 05/2007
4	Thrombocytopenia (Thrombopenia) 10/2016 - 01/2009
4	Neutropenia 12/2015 - 06/2006
3	Tics (Tic) 01/2021 - 10/2015
3	Fibrosis (Cirrhosis) 01/2019 - 01/2002
3	Body Weight (Weight, Body) 01/2019 - 11/2015
3	Anemia 07/2017 - 06/2006
3	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2017 - 07/2010
3	Embryonal Carcinoma 01/2017 - 10/2003
3	Edema (Dropsy) 12/2015 - 05/2007
3	Asthenia 12/2015 - 05/2007
3	Carcinoma (Carcinomatosis) 02/2015 - 01/2011
3	Clear-cell metastatic renal cell carcinoma 03/2014 - 05/2013
3	Pneumonia (Pneumonitis) 08/2013 - 08/2008
3	Seminoma 11/2003 - 01/2002
2	Inflammation (Inflammations) 10/2022 - 01/2022
2	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 01/2019
2	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 10/2020
2	Carcinogenesis 01/2019 - 03/2008
2	Nausea 10/2018 - 09/2007
2	Necrosis 01/2017 - 07/2011
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2017 - 03/2011

Drug/Important Bio-Agent (IBA)

101	Sunitinib (Sutent)FDA Link 10/2022 - 01/2006
47	Everolimus FDA Link 01/2022 - 12/2006
37	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2022 - 08/2005
31	NivolumabIBA 01/2022 - 05/2015
29	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2002
20	Immune Checkpoint InhibitorsIBA 10/2022 - 09/2016
19	Tyrosine Kinase InhibitorsIBA 01/2022 - 05/2006
19	Interferon-alpha (Interferon Alfa)IBA 08/2014 - 01/2002
17	Bevacizumab (Avastin)FDA Link 02/2022 - 12/2006
16	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2022 - 01/2006
16	Axitinib (AG 013736)IBA 10/2022 - 11/2007
15	cabozantinibIBA 01/2022 - 11/2015
15	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2002
14	pazopanib FDA Link 01/2021 - 08/2013
13	IpilimumabIBA 01/2022 - 04/2018
13	TOR Serine-Threonine KinasesIBA 01/2019 - 09/2007
12	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 01/2002
12	Sorafenib (BAY 43-9006)FDA Link 08/2015 - 12/2006
11	Pharmaceutical PreparationsIBA 01/2021 - 09/2004
10	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2010
10	InterferonsIBA 02/2016 - 04/2007
9	lenvatinibIBA 01/2022 - 11/2015
9	CytokinesIBA 01/2018 - 09/2004
8	atezolizumabIBA 02/2022 - 01/2018
8	temsirolimus FDA Link 10/2014 - 12/2006
7	Biological ProductsIBA 01/2022 - 01/2002
6	Proteins (Proteins, Gene)FDA Link 01/2019 - 07/2007
6	Paclitaxel (Taxol)FDA LinkGeneric 01/2016 - 09/2005
5	B7-H1 AntigenIBA 01/2022 - 01/2019
5	Bleomycin (Blenoxane)FDA LinkGeneric 01/2021 - 01/2002
5	PlatinumIBA 10/2019 - 01/2002
5	Ifosfamide FDA LinkGeneric 01/2016 - 09/2005
5	MTOR InhibitorsIBA 04/2014 - 08/2010
4	avelumabIBA 10/2022 - 01/2019
4	LigandsIBA 02/2022 - 03/2016
4	pembrolizumabIBA 01/2021 - 03/2019
4	Hemoglobins (Hemoglobin)IBA 06/2017 - 10/2006
4	Tumor Biomarkers (Tumor Markers)IBA 10/2014 - 10/2007
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2013 - 01/2006
3	RNA (Ribonucleic Acid)IBA 01/2022 - 12/2010
3	Lipase (Acid Lipase)FDA Link 10/2019 - 06/2006
3	Interleukin-2 (IL2)IBA 12/2017 - 08/2008
3	Imatinib Mesylate (Gleevec)FDA Link 01/2017 - 05/2006
3	Carboplatin (JM8)FDA LinkGeneric 10/2015 - 01/2007
3	Alkaline PhosphataseIBA 01/2015 - 10/2006
3	Carbonic Anhydrase IXIBA 10/2014 - 04/2007
2	MicroRNAs (MicroRNA)IBA 06/2020 - 12/2010
2	Amylases FDA Link 10/2019 - 12/2015
2	Alanine Transaminase (SGPT)IBA 10/2019 - 08/2013
2	NucleotidesIBA 01/2019 - 02/2016
2	Phosphotransferases (Kinase)IBA 10/2018 - 05/2006

Therapy/Procedure

127	Therapeutics 10/2022 - 01/2002
40	Drug Therapy (Chemotherapy) 01/2021 - 01/2002
27	Nephrectomy 01/2022 - 12/2002
23	Lymph Node Excision (Lymph Node Dissection) 01/2020 - 11/2002
10	Immunotherapy 01/2022 - 01/2016
6	Aftercare (After-Treatment) 01/2021 - 06/2003
6	Adjuvant Chemotherapy 01/2020 - 11/2002
4	Salvage Therapy 02/2016 - 01/2007
3	Drug Tapering 03/2015 - 08/2010
3	Radiotherapy 02/2015 - 11/2003